<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Artrya Limited — News on 6ix</title>
<link>https://6ix.com/company/artrya-ltd</link>
<description>Latest news and press releases for Artrya Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 30 Apr 2026 03:35:14 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/artrya-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683662ae78dffbe2df15c768.webp</url>
<title>Artrya Limited</title>
<link>https://6ix.com/company/artrya-ltd</link>
</image>
<item>
<title>March Quarterly Activities Report and Appendix 4C</title>
<link>https://6ix.com/company/artrya-ltd/news/march-quarterly-activities-report-and-appendix-4c-2</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/march-quarterly-activities-report-and-appendix-4c-2</guid>
<pubDate>Thu, 30 Apr 2026 03:35:14 GMT</pubDate>
<description>March Quarterly Activities Report and Appendix 4C</description>
</item>
<item>
<title>Update - S&P DJI March 2026 Rebalance of the All Ordinaries</title>
<link>https://6ix.com/company/artrya-ltd/news/update-sandp-dji-march-2026-rebalance-of-the-all-ordinaries-8</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/update-sandp-dji-march-2026-rebalance-of-the-all-ordinaries-8</guid>
<pubDate>Tue, 10 Mar 2026 10:49:03 GMT</pubDate>
<description>Update - S&P DJI March 2026 Rebalance of the All Ordinaries</description>
</item>
<item>
<title>S&P DJI Announces March 2026 Quarterly Rebalance</title>
<link>https://6ix.com/company/artrya-ltd/news/sandp-dji-announces-march-2026-quarterly-rebalance-40</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/sandp-dji-announces-march-2026-quarterly-rebalance-40</guid>
<pubDate>Fri, 06 Mar 2026 11:26:03 GMT</pubDate>
<description>S&P DJI Announces March 2026 Quarterly Rebalance</description>
</item>
<item>
<title>Appendix 4D and Interim Financial Report</title>
<link>https://6ix.com/company/artrya-ltd/news/appendix-4d-and-interim-financial-report-27</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/appendix-4d-and-interim-financial-report-27</guid>
<pubDate>Wed, 25 Feb 2026 14:19:12 GMT</pubDate>
<description>Appendix 4D and Interim Financial Report</description>
</item>
<item>
<title>Quarterly Activities/Appendix 4C Cash Flow Report</title>
<link>https://6ix.com/company/artrya-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-21</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-21</guid>
<pubDate>Fri, 30 Jan 2026 04:00:14 GMT</pubDate>
<description>Quarterly Activities/Appendix 4C Cash Flow Report</description>
</item>
<item>
<title>Cone Health Becomes Third U.S. Customer</title>
<link>https://6ix.com/company/artrya-ltd/news/cone-health-becomes-third-us-customer</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/cone-health-becomes-third-us-customer</guid>
<pubDate>Tue, 23 Dec 2025 03:56:04 GMT</pubDate>
<description>Cone Health Becomes Third U.S. Customer</description>
</item>
<item>
<title>First Revenues from Salix Coronary Plaque Module</title>
<link>https://6ix.com/company/artrya-ltd/news/first-revenues-from-salix-coronary-plaque-module</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/first-revenues-from-salix-coronary-plaque-module</guid>
<pubDate>Fri, 12 Dec 2025 03:54:15 GMT</pubDate>
<description>First Revenues from Salix Coronary Plaque Module</description>
</item>
<item>
<title>Second US Commercial Customer - Northeast Georgia</title>
<link>https://6ix.com/company/artrya-ltd/news/second-us-commercial-customer-northeast-georgia</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/second-us-commercial-customer-northeast-georgia</guid>
<pubDate>Mon, 08 Dec 2025 03:44:13 GMT</pubDate>
<description>Second US Commercial Customer - Northeast Georgia</description>
</item>
<item>
<title>S&P DJI Announces December 2025 Quarterly Rebalance</title>
<link>https://6ix.com/company/artrya-ltd/news/sandp-dji-announces-december-2025-quarterly-rebalance-19</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/sandp-dji-announces-december-2025-quarterly-rebalance-19</guid>
<pubDate>Fri, 05 Dec 2025 11:27:03 GMT</pubDate>
<description>S&P DJI Announces December 2025 Quarterly Rebalance</description>
</item>
<item>
<title>SAPPHIRE Study Expands With Inclusion of Ascension</title>
<link>https://6ix.com/company/artrya-ltd/news/sapphire-study-expands-with-inclusion-of-ascension</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/sapphire-study-expands-with-inclusion-of-ascension</guid>
<pubDate>Thu, 13 Nov 2025 03:50:09 GMT</pubDate>
<description>SAPPHIRE Study Expands With Inclusion of Ascension</description>
</item>
<item>
<title>Mass General Brigham to Participate in SAPPHIRE Study</title>
<link>https://6ix.com/company/artrya-ltd/news/mass-general-brigham-to-participate-in-sapphire-study</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/mass-general-brigham-to-participate-in-sapphire-study</guid>
<pubDate>Wed, 05 Nov 2025 03:59:15 GMT</pubDate>
<description>Mass General Brigham to Participate in SAPPHIRE Study</description>
</item>
<item>
<title>Completion of Placement and Cleansing Notice</title>
<link>https://6ix.com/company/artrya-ltd/news/completion-of-placement-and-cleansing-notice</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/completion-of-placement-and-cleansing-notice</guid>
<pubDate>Fri, 31 Oct 2025 02:57:07 GMT</pubDate>
<description>Completion of Placement and Cleansing Notice</description>
</item>
<item>
<title>Completion of Share Purchase Plan</title>
<link>https://6ix.com/company/artrya-ltd/news/completion-of-share-purchase-plan-12</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/completion-of-share-purchase-plan-12</guid>
<pubDate>Fri, 03 Oct 2025 05:38:11 GMT</pubDate>
<description>Completion of Share Purchase Plan</description>
</item>
<item>
<title>Successful A$75 million placement and launch of SPP</title>
<link>https://6ix.com/company/artrya-ltd/news/successful-adollar75-million-placement-and-launch-of-spp</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/successful-adollar75-million-placement-and-launch-of-spp</guid>
<pubDate>Tue, 09 Sep 2025 03:41:12 GMT</pubDate>
<description>Successful A$75 million placement and launch of SPP</description>
</item>
<item>
<title>Trading Halt</title>
<link>https://6ix.com/company/artrya-ltd/news/trading-halt-287</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/trading-halt-287</guid>
<pubDate>Fri, 05 Sep 2025 03:28:18 GMT</pubDate>
<description>Trading Halt</description>
</item>
<item>
<title>FDA clearance of Salix® Coronary Plaque module</title>
<link>https://6ix.com/company/artrya-ltd/news/fda-clearance-salix-coronary-plaque-114300759</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/fda-clearance-salix-coronary-plaque-114300759</guid>
<pubDate>Thu, 21 Aug 2025 11:43:00 GMT</pubDate>
<description>Artrya Limited (ASX: AYA) (Artrya or the Company), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce it has received 510(k) clearance from the U.S. Food and Drug Administration (the FDA) for Artrya's proprietary, Salix® Coronary Plaque module. This regulatory clearance is a major milestone in Artrya's U.S. market launch which commenced in July and wi</description>
</item>
<item>
<title>FDA clearance of Salix Coronary Plaque module</title>
<link>https://6ix.com/company/artrya-ltd/news/fda-clearance-of-salix-coronary-plaque-module</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/fda-clearance-of-salix-coronary-plaque-module</guid>
<pubDate>Thu, 21 Aug 2025 02:49:42 GMT</pubDate>
<description>FDA clearance of Salix Coronary Plaque module</description>
</item>
<item>
<title>Appendix 4E and Annual Financial Statements</title>
<link>https://6ix.com/company/artrya-ltd/news/appendix-4e-and-annual-financial-statements-3</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/appendix-4e-and-annual-financial-statements-3</guid>
<pubDate>Wed, 20 Aug 2025 13:27:11 GMT</pubDate>
<description>Appendix 4E and Annual Financial Statements</description>
</item>
<item>
<title>AYA Signs US$0.6m Five Year Contract with Tanner Health</title>
<link>https://6ix.com/company/artrya-ltd/news/aya-signs-usdollar06m-five-year-contract-with-tanner-health</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/aya-signs-usdollar06m-five-year-contract-with-tanner-health</guid>
<pubDate>Thu, 10 Jul 2025 03:16:04 GMT</pubDate>
<description>AYA Signs US$0.6m Five Year Contract with Tanner Health</description>
</item>
<item>
<title>Artrya Leadership Transition</title>
<link>https://6ix.com/company/artrya-ltd/news/artrya-leadership-transition</link>
<guid isPermaLink="true">https://6ix.com/company/artrya-ltd/news/artrya-leadership-transition</guid>
<pubDate>Tue, 01 Jul 2025 03:26:09 GMT</pubDate>
<description>Artrya Leadership Transition</description>
</item>
</channel>
</rss>